50. Early clinical markers of CNS involvement in MPS II (original) (raw)
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials
Hadhami Ben Turkia
Blood Cells, Molecules, and Diseases, 2016
View PDFchevron_right
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study
Ari Zimran
American Journal of Hematology, 2013
View PDFchevron_right
Enzyme replacement and substrate reduction therapy for Gaucher disease
Bruno Bembi
Protocols, 1996
View PDFchevron_right
Individualization of long-term enzyme replacement therapy for Gaucher disease
Gregory Pastores
Genetics in Medicine, 2005
View PDFchevron_right
Enzyme replacement treatment in type 1 and type 3 Gaucher's disease
Bruno Bembi
The Lancet, 1994
View PDFchevron_right
Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment
Thiago Muniz
Revista Brasileira de Hematologia e Hemoterapia, 2014
View PDFchevron_right
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review
Christopher McCabe
View PDFchevron_right
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
Atul Mehta
American journal of hematology, 2015
View PDFchevron_right
Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy
Mario Cabrera
Clinica Chimica Acta, 2004
View PDFchevron_right
Enzyme replacement therapy in pediatric patients with Gaucher disease: What should we use as maintenance dosage?
Jacques Galipeau
Molecular Genetics and Metabolism, 2009
View PDFchevron_right
Optimal therapy in Gaucher disease
Ozlem Goker-alpan
Therapeutics and Clinical Risk Management, 2010
View PDFchevron_right
Achievement of Therapeutic Goals Over 2 Years of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease
Pilar Giraldo
Molecular Genetics and Metabolism, 2012
View PDFchevron_right
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
Pilar Giraldo
Molecular Genetics and Metabolism Reports, 2016
View PDFchevron_right
Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study
Katrina Wyatt
Journal of Inherited Metabolic Disease, 2014
View PDFchevron_right
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease
Atul Mehta
American journal of hematology, 2015
View PDFchevron_right
Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease
George Hermann
Pediatric Research, 1992
View PDFchevron_right
Relationship between Glucocerebrosidase Activity and clinical response to Enzyme Replacement Therapy in patients with Gaucher Disease type I
Vicente Giner
Basic & clinical pharmacology & toxicology, 2018
View PDFchevron_right
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1
Katherine Kacena
Genetics in Medicine, 2009
View PDFchevron_right
Safety and efficacy of long-term enzyme replacement therapy with velaglucerase alfa in patients with type 1 Gaucher disease transitioned from imiglucerase
Pilar Giraldo
Molecular Genetics and Metabolism, 2014
View PDFchevron_right
Enzyme-replacement therapy for Gaucher's disease
Bruno Bembi
The New England journal of medicine, 1991
View PDFchevron_right
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience
Ari Zimran
Blood, 2010
View PDFchevron_right
The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease
Edythe Wiggs
The Journal of Pediatrics, 2001
View PDFchevron_right
Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Figen Gürakan
The Turkish journal of pediatrics
View PDFchevron_right
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase
Nicola Longo
Molecular genetics and metabolism, 2015
View PDFchevron_right
Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher Disease
Paige Kaplan, T. Hangartner, Gregory Pastores
Journal of Bone and Mineral Research, 2006
View PDFchevron_right
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
Pilar Giraldo
American journal of hematology, 2016
View PDFchevron_right